Table 3.

Patient characteristics.

Baseline	Placebo group (n = 20)	Liraglutide group (n = 14)	Placebo vs. liraglutide group
	mean (SEM)	mean (SEM)	P
Fasting plasma-glucose (mmol/L)	5.8 (0.2)	5.6 (0.2)	0.24
Glycated hemoglobin (HbAlc)	0.056 (0.001)	0.055 (0.0006)	0.41
Plasma-cholesterol total(mmol/L)	5.9 (0.3)	5.7 (0.2)	0.67
Weight (kg)	77.8 (3.0)	74.1 (2.1)	0.38
Body Mass Index (BMI) (kg/m	25.1 (0.7)	25.1 (1.0)	0.96
Systolic blood pressure (mmHg)	149.7 (4.3)	144.1 (6.3)	0.46
Diastolic blood pressure (mmHg)	87.5 (2.4)	83.9 (2.5)	0.32
Heart rate (bpm)	62.7 (3.2)	64.8 (2.8)	0.64
After 6 Months	Placebo group (n = 20)	Liraglutide group (n = 14)	Placebo vs. liraglutide group	Change placebo vs. change liraglutide group
	mean (SEM)	mean (SEM)	P	P
Fasting plasma-glucose (mmol/L)	5.6 (0.1)	5.1 (0.1)	0.0041*	0.10
Glycated hemoglobin (HbAlc)	0.056 (0.0008)	0.054 (0.0008)	0.23	0.68
Plasma-cholesterol total (mmol/L)	5.5 (0.3)	5.1 (0.2)	0.27	0.12
Weight (kg)	76.1 (2.8)	69.2 (2.0)	0.071	0.0083*
Body Mass Index (BMI) (kg/m	24.6 (0.7)	23.4 (0.9)	0.26	0.0069*
Systolic blood pressure (mmHg)	151.4 (4.8)	132.4 (5.6)	0.015*	0.013*
Diastolic blood pressure (mmHg)	88.8 (2.7)	80.3 (2.5)	0.035*	0.19
Heart rate (bpm)	68.4 (4.3)	66.1 (1.8)	0.67	0.46

Data are presented as mean (SEM), and P-value is calculated using paired/independent samples t-test. ^∗P < 0.05.